Literature DB >> 14555814

Estrogen and enalapril attenuate the development of right ventricular hypertrophy induced by monocrotaline in ovariectomized rats.

Byung Hoon Ahn1, Hwan Ki Park, Hyun Gug Cho, Hae Ahm Lee, Young Man Lee, Eun Kyoung Yang, Won Jung Lee.   

Abstract

The present study evaluated the importance of ovarian functions and the renin-angiotensin system in the progression of the right ventricular (RV) hypertrophy. Female Sprague-Dawley rats were bilaterally ovariectomized (Ovx) and injected with monocrotaline (MCT, 60 mg/kg, sc). Four weeks after MCT-treatment, only the male and Ovx female rats showed marked RV hypertrophy. The hypertrophied RV of the male-MCT and Ovx-MCT rats exhibited remarkably elevated renin mRNA levels. Gene expression levels of angiotensinogen, TGF-beta1, and endothelin-1 in the hypertrophied RV also increased, but to the less degree than did the renin mRNA. To investigate beneficial effects of estrogen or enalapril on progression of the pulmonary hypertension and RV hypertrophy, histological changes of the lung and heart were examined. Sham-MCT female rats showed histological changes indicating pulmonary hypertension without RV hypertrophy. In contrast, Ovx-MCT rats showed marked RV hypertrophy with pathological changes, denoting severe pulmonary and myocardial injuries. Estrogen-or enalapril-treated Ovx-MCT rats did not show RV hypertrophy, and showed remarkably ameliorated ultrastructural changes in the lung and RV. These results from this rat model suggest that both estrogen and inhibition of the renin-angiotensin system have protective functions against the development of the pulmonary hypertension and cardiac remodeling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555814      PMCID: PMC3055117          DOI: 10.3346/jkms.2003.18.5.641

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  11 in total

Review 1.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

Review 2.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 3.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

Review 4.  Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.

Authors:  Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

5.  Sex differences in stretch-dependent effects on tension and Ca(2+) transient of rat trabeculae in monocrotaline pulmonary hypertension.

Authors:  Oleg Lookin; Daniil Kuznetsov; Yuri Protsenko
Journal:  J Physiol Sci       Date:  2014-10-31       Impact factor: 2.781

6.  Roles of Genetic Predisposition in the Sex Bias of Pulmonary Pathophysiology, as a Function of Estrogens : Sex Matters in the Prevalence of Lung Diseases.

Authors:  An Huang; Sharath Kandhi; Dong Sun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females.

Authors:  Yvonne Dempsie; Margaret Nilsen; Kevin White; Kirsty M Mair; Lynn Loughlin; Noona Ambartsumian; Marlene Rabinovitch; Margaret R Maclean
Journal:  Respir Res       Date:  2011-12-20

8.  Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice.

Authors:  Balram Neupane; Akylbek Sydykov; Kabita Pradhan; Christina Vroom; Christiane Herden; Srikanth Karnati; Hossein Ardeschir Ghofrani; Sergey Avdeev; Süleyman Ergün; Ralph Theo Schermuly; Djuro Kosanovic
Journal:  Respir Res       Date:  2020-06-03

Review 9.  Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.

Authors:  K M Mair; A K Z Johansen; A F Wright; E Wallace; M R MacLean
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 10.  Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.

Authors:  José L Sánchez-Gloria; Horacio Osorio-Alonso; Abraham S Arellano-Buendía; Roxana Carbó; Adrián Hernández-Díazcouder; Carlos A Guzmán-Martín; Ivan Rubio-Gayosso; Fausto Sánchez-Muñoz
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.